Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Repligen
Repligen
Activities:
Distribution
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Ecolab Life Sciences and Repligen launch novel chromatography resin for large-scale biologic manufacturing
Purolite's DurA Cycle is a protein A chromatography resin that can optimise large-scale purification processes
Regulatory
Purolite and Repligen launch a novel CH1 affinity resin for the purification of specialised mAbs
They launch Praesto CH1 a novel 70μm agarose-based affinite resin designed to purified specialised mAbs such as bispecifics or recombinant antibody fragments
Manufacturing
Sartorius and Repligen combine technologies for integrated bioreactor system
The two companies have incorporated Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor to simplify upstream process intensification
Manufacturing
Repligen partners with Daylight on mid-infrared tech
Through this agreement, Repligen will assume responsibility for the commercialisation of DRS Daylight’s Culpeo product
Manufacturing
Repligen plans Polymem acquisition to expand hollow fibre capabilities
The CDMO has made the acquisition to significantly expands hollow fibre membrane and module production capabilities for both industrial and bioprocessing markets
Manufacturing
Sartorius and Repligen collaborate on perfusion-enabled bioreactors
Joint technology to control cell growth, fluid management and cell retention would simplify development and cGMP manufacture of biological drugs
Manufacturing
Repligen completes expansion of US manufacturing facility in Massachusetts
More than doubles capacity for OPUS pre-packed chromatography columns
Subscribe now